Related Experiment Videos
Sodium valproate monotherapy in childhood epilepsy
Brain & Development
|January 1, 1986
Summary
Valproate monotherapy effectively controlled various epilepsies in children, with absence and benign myoclonic types showing best responses. Discontinuation led to relapse in some generalized tonic-clonic epilepsy cases but not others.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Valproate is a common antiepileptic drug used in children.
- Understanding its efficacy and safety in monotherapy is crucial for treatment optimization.
Purpose of the Study:
- To evaluate the efficacy and tolerability of valproate monotherapy in pediatric epilepsy.
- To assess seizure recurrence after valproate discontinuation in different epilepsy types.
Main Methods:
- Prospective follow-up of 154 pediatric patients on valproate monotherapy for 5-27 months.
- Analysis of seizure control, adverse effects, and relapse rates after treatment cessation.
Main Results:
- Valproate monotherapy showed good control for absence epilepsies, benign myoclonic epilepsies, and epilepsies with tonic-clonic seizures on awakening.
- Improvement was noted in 13/14 patients with primary generalized epilepsy on monotherapy.
- Mild to moderate adverse effects occurred in 16% of patients.
- No relapse was observed in absence, benign myoclonic, infantile spasms, or benign partial epilepsy after discontinuation.
- Two-thirds of patients with generalized tonic-clonic seizures on awakening relapsed post-cessation.
Conclusions:
- Valproate monotherapy is effective for several pediatric epilepsy syndromes, particularly absence and benign myoclonic types.
- While generally well-tolerated, careful consideration of discontinuation is needed for generalized tonic-clonic seizures on awakening due to relapse risk.